Journal
JOURNAL OF OPHTHALMOLOGY
Volume 2015, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2015/250812
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81371060]
- Wenzhou Medical University, Wenzhou, China [QTJ11018]
- scientific research foundation from Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University [KYQD130501]
- Jiangsu Province Foundation for Innovative Research Team
- National Institutes of Health (NIH) [EY023543]
Ask authors/readers for more resources
Retinal degenerative diseases are one of the important refractory ophthalmic diseases, featured with apoptosis of photoreceptor cells. Histone acetylation and deacetylation can regulate chromosome assembly, gene transcription, and posttranslational modification, which are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. The histone deacetylase inhibitors (HDACis) have the ability to cause hyperacetylation of histone and nonhistone proteins, resulting in a variety of effects on cell proliferation, differentiation, anti-inflammation, and anti-apoptosis. Several HDACis have been approved for clinical trials to treat cancer. Studies have shown that HDACis have neuroprotective effects in nervous system damage. In this paper, we will summarize the neuroprotective effects of common HDACis in retinal degenerative diseases and make a prospect to the applications of HDACis in the treatment of retinal degenerative diseases in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available